Manhattan Associates, Inc. (MANH) At $42.68 Forms Bottom; 683 Capital Management Increased By $443,655 Its Galmed Pharmaceuticals LTD (GLMD) Stake

Manhattan Associates, Inc. (MANH) formed multiple bottom with $40.55 target or 5.00% below today’s $42.68 share price. Manhattan Associates, Inc. (MANH) has $2.90B valuation. The stock decreased 0.67% or $0.29 during the last trading session, reaching $42.68. About 796,895 shares traded or 10.82% up from the average. Manhattan Associates, Inc. (NASDAQ:MANH) has declined 22.39% since February 21, 2017 and is downtrending. It has underperformed by 39.09% the S&P500.

683 Capital Management Llc increased Galmed Pharmaceuticals Ltd (GLMD) stake by 9.86% reported in 2017Q3 SEC filing. 683 Capital Management Llc acquired 49,295 shares as Galmed Pharmaceuticals Ltd (GLMD)’s stock rose 17.66%. The 683 Capital Management Llc holds 549,295 shares with $5.02 million value, up from 500,000 last quarter. Galmed Pharmaceuticals Ltd now has $67.87 million valuation. The stock decreased 9.97% or $0.59 during the last trading session, reaching $5.33. About 143,233 shares traded or 39.34% up from the average. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 0.41% since February 21, 2017 and is uptrending. It has underperformed by 16.29% the S&P500.

Among 7 analysts covering Manhattan Assoc (NASDAQ:MANH), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Manhattan Assoc has $80 highest and $45 lowest target. $68.40’s average target is 60.26% above currents $42.68 stock price. Manhattan Assoc had 14 analyst reports since July 22, 2015 according to SRatingsIntel. As per Thursday, April 28, the company rating was downgraded by William Blair. The stock of Manhattan Associates, Inc. (NASDAQ:MANH) has “Buy” rating given on Wednesday, October 21 by Benchmark. On Monday, January 9 the stock rating was downgraded by Raymond James to “Mkt Perform”. The firm has “Buy” rating given on Wednesday, July 22 by Benchmark. SunTrust maintained the shares of MANH in report on Wednesday, February 7 with “Buy” rating. The rating was maintained by KeyBanc Capital Markets with “Hold” on Wednesday, August 23. The stock of Manhattan Associates, Inc. (NASDAQ:MANH) has “Buy” rating given on Wednesday, November 15 by SunTrust. Lake Street initiated Manhattan Associates, Inc. (NASDAQ:MANH) on Monday, October 19 with “Buy” rating. Benchmark maintained Manhattan Associates, Inc. (NASDAQ:MANH) on Wednesday, February 1 with “Buy” rating. Brean Capital initiated the shares of MANH in report on Tuesday, January 12 with “Buy” rating.

Investors sentiment increased to 1.33 in Q3 2017. Its up 0.26, from 1.07 in 2017Q2. It improved, as 35 investors sold Manhattan Associates, Inc. shares while 67 reduced holdings. 35 funds opened positions while 101 raised stakes. 72.05 million shares or 1.48% less from 73.13 million shares in 2017Q2 were reported. Amica Mutual Ins holds 0.03% or 8,642 shares in its portfolio. Arizona State Retirement Sys holds 0.02% or 39,031 shares. Invesco Limited owns 28,178 shares or 0% of their US portfolio. Alliancebernstein Ltd Partnership reported 44,067 shares. Moreover, Etrade Capital Mngmt Limited Liability Corporation has 0.02% invested in Manhattan Associates, Inc. (NASDAQ:MANH). Metropolitan Life Ins Com has 0.02% invested in Manhattan Associates, Inc. (NASDAQ:MANH). Oppenheimer Asset Management invested 0.03% of its portfolio in Manhattan Associates, Inc. (NASDAQ:MANH). Blackrock Inc accumulated 5.86M shares. Moreover, State Street has 0.01% invested in Manhattan Associates, Inc. (NASDAQ:MANH). 40,051 are held by Tudor Corporation Et Al. Arrowstreet Capital Limited Partnership invested in 25,200 shares. Riverhead Management Limited Liability, a Delaware-based fund reported 4,285 shares. Legal & General Group Public Ltd Liability Com has 0% invested in Manhattan Associates, Inc. (NASDAQ:MANH) for 63,058 shares. Pacad accumulated 7,200 shares. Wcm Investment Mngmt Ca owns 12,870 shares.

Analysts await Manhattan Associates, Inc. (NASDAQ:MANH) to report earnings on April, 19. They expect $0.26 EPS, down 35.00% or $0.14 from last year’s $0.4 per share. MANH’s profit will be $17.67 million for 41.04 P/E if the $0.26 EPS becomes a reality. After $0.40 actual EPS reported by Manhattan Associates, Inc. for the previous quarter, Wall Street now forecasts -35.00% negative EPS growth.

683 Capital Management Llc decreased Allergan Plc stake by 20,000 shares to 62,000 valued at $12.71M in 2017Q3. It also reduced Warrior Met Coal Inc stake by 257,200 shares and now owns 700,000 shares. National Energy Services Reu was reduced too.

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Galmed Pharmaceuticals Ltd has $32 highest and $1400 lowest target. $20.40’s average target is 282.74% above currents $5.33 stock price. Galmed Pharmaceuticals Ltd had 8 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has “Hold” rating given on Wednesday, February 14 by Maxim Group. Maxim Group maintained the stock with “Buy” rating in Monday, July 31 report. As per Thursday, August 13, the company rating was maintained by Roth Capital. The firm has “Buy” rating given on Tuesday, August 8 by H.C. Wainwright. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has “Buy” rating given on Monday, March 28 by H.C. Wainwright.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: